Business
Elon Musk
Elon Musk (Craig T Fruchtman/Getty Images)

Musk’s xAI seeking a $50 billion valuation is a lesson in chutzpah

Musk is raising $6 billion for xAI at a nosebleed valuation, despite low revenue.

It’s a good time to fundraise for an AI startup: less than two months after OpenAI raised $6.6 billion at a $157 billion valuation, CNBC reported that Elon Musk’s AI startup, xAI, is raising $6 billion at a $50 billion valuation, with $5 billion to come from funds in the Middle East. The funding round is expected to close next week, CNBC said.

One interesting detail about this fundraise: xAI’s revenue is likely far below competitors OpenAI and Anthropic.

In October, The Information reported that OpenAI was on pace for $4 billion in 2024 revenue, driven mostly by ChatGPT. Previously The Information reported that Anthropic, the owner of generative-AI platform Claude, was on pace for $1 billion in annualized revenue, with the majority coming from API fees. At the time, Anthropic was looking to raise new funding at a $30 billion to $40 billion valuation.

Unlike these two competitors’ 10-digit revenue figures, xAI’s revenue is likely much, much lower. Until mid-October, when xAI added a tool to let developers create applications powered by its chatbot, Grok, the company’s only known revenue stream was X Premium subscriptions, which gave users access to Grok. On October 15, TechCrunch reported that X had made a total of $200 million from in-app purchases since X Premium was initially launched as Twitter Blue, meaning that any revenue cut earmarked for xAI is likely in the tens of millions, a far cry from the billion-dollar figures of its competitors.

But xAI does have a few things working in its favor.

The company claims it has the world’s largest data center in Memphis, Tennessee, which Nvidia CEO Jensen Huang called “easily the fastest supercomputer on the planet.” The company is also already integrated with social-media platform X, and there’s an opportunity for xAI to work with Musk’s other companies, like Tesla.

We can’t forget that Musk was one of OpenAI’s founders (he’s now suing the company), and his relationship with President-elect Trump could prove advantageous when it comes to new AI regulations.

Basically, a $50 billion valuation is as much a bet on Musk as it is on xAI.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.